Fig. 1From: Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinomaThe main process of this clinical trial. Abbreviation: AG chemotherapy, nab-paclitaxel plus gemcitabine; RECIST, Response Evaluation Criteria in Solid Tumors. irRECIST, the immune-related RECISTBack to article page